Document center

European Charter for Access to Research Infrastructures Principles and Guidelines for Access and Related Services (Nov 2024)

Published on | 1 year ago

Programmes Research Infrastructures

The European Charter for Access to Research Infrastructures sets out non-regulatory principles and guidelines to be used as a reference when defining Access policies for Research Infrastructures and related services. While not having any legally binding nature, Research Infrastructures are encouraged to use this Charter as a reference when updating existing or defining new Access policies. In addition, the funding organisations of Research Infrastructures are invited to promote this Charter’s provisions. The update of the Charter published in 2015 is part of the ERA Policy Agenda 2022- 2024. (from the abstract of the study)

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.